Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.

Authors

Sonia Pernas

Institut Català d'Oncologia, IDIBELL, L’Hospitalet, Barcelona, MA, Spain

Sonia Pernas , Carmen Hinojo , Javier Pascual , Sercan Aksoy , Glen Clack , Stuart McIntosh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.

First Author: Claudia Omarini

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.

First Author: Geoffrey Shapiro

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.

First Author: Melinda L. Telli

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

First Author: Timothy A. Yap